Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board

Akari Therapeutics Plc

Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.
Abizer Gaslightwala appointed as Class A director effective Dec 16, 2024; term expires at 2025 AGM.
Michael Grissinger resigned from board on Dec 16, 2024; no disagreement with company operations.
Gaslightwala is SVP at Jazz Pharma, previously at Amgen and Pfizer; deemed independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.